Insider · CIK 0001258693
Grant Pickering
Files at LONA (Athira Pharma, Inc.), PCVX (Vaxcyte, Inc.). First filing Nov 4, 2024, latest Jul 28, 2026.
In brief
Grant Pickering files SEC Form 4 as CEO and director at PCVX (Vaxcyte, Inc.), and also at LONA (Athira Pharma, Inc.). Since Nov 4, 2024, Grant Pickering has reported 0 open-market buys worth $0 and 7 open-market sells worth $7.1M, the latest filed on Jul 28, 2026.
A track record needs three past buys with six months of prices behind them; Grant Pickering has 0, so none is measured yet.
The newest scored trade: sold $1.0M of PCVX on Jul 27, 2026, filed Jul 28, 2026, scored 30 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 3 sells worth $3.6M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PCVX: Vaxcyte, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Vaxcyte, Inc. | $1.0M 18,198 shares | -4% | +87% from low-12% from high | |
| 45Moderate | Vaxcyte, Inc. | $1.3M 24,237 shares | -5% | +91% from low-10% from high | |
| 30Weak | Vaxcyte, Inc. | $1.3M 24,461 shares | -5% | +73% from low-18% from high | |
| 32Weak | Vaxcyte, Inc. | $218k 2,366 shares | -2% | - | |
| 45Moderate | Vaxcyte, Inc. | $1.4M 15,000 shares | -3% | - | |
| 18Weak | Vaxcyte, Inc. | $246k 2,366 shares | -2% | - | |
| 45Moderate | Vaxcyte, Inc. | $1.6M 15,000 shares | -3% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 27, 2026 | PCVX Vaxcyte, Inc. | 18,198 0.01% of outstanding | $997k | Jul 27, 2026 | $2.6M |
| Jun 26, 2026 | PCVX Vaxcyte, Inc. | 24,237 0.02% of outstanding | $1.3M | Jun 26, 2026 | $1.3M |
| Jun 18, 2026 | PCVX Vaxcyte, Inc. | 24,461 0.02% of outstanding | $1.3M | Jun 18, 2026 | none |
| Dec 9, 2024 | PCVX Vaxcyte, Inc. | 2,366 0.00% of outstanding | $222k | Dec 9, 2024 | $10M |
| Dec 2, 2024 | PCVX Vaxcyte, Inc. | 15,000 0.01% of outstanding | $1.4M | Dec 2, 2024 | $8.9M |
| Nov 7, 2024 | PCVX Vaxcyte, Inc. | 2,366 0.00% of outstanding | $246k | Nov 7, 2024 | $10M |
| Nov 1, 2024 | PCVX Vaxcyte, Inc. | 15,000 0.01% of outstanding | $1.6M | Nov 1, 2024 | $8.4M |
| Dec 26, 2023 | PCVX Vaxcyte, Inc. | 15,000 0.02% of outstanding | $921k | Dec 26, 2023 | $1.8M |
| Dec 1, 2023 | PCVX Vaxcyte, Inc. | 2,618 0.00% of outstanding | $136k | Dec 1, 2023 | $2.6M |
| Nov 24, 2023 | PCVX Vaxcyte, Inc. | 15,000 0.02% of outstanding | $731k | Nov 24, 2023 | $1.9M |
| Nov 1, 2023 | PCVX Vaxcyte, Inc. | 2,618 0.00% of outstanding | $126k | Nov 1, 2023 | $1.8M |
| Oct 23, 2023 | PCVX Vaxcyte, Inc. | 15,000 0.02% of outstanding | $699k | Oct 23, 2023 | $1.1M |
Transactions
The newest 50 of 70 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | PCVX Vaxcyte, Inc. | FTax withholding Common Stock | -17,056 | $60.36 | $1.0M | 429,902 | 34 d ago |
| Aug 31, 2026 | PCVX Vaxcyte, Inc. | FTax withholding Common Stock | -2,862 | $60.74 | $174k | 450,385 | 41 d ago |
| Sep 2, 2026 | PCVX Vaxcyte, Inc. | FTax withholding Common Stock | -3,427 | $61.58 | $211k | 446,958 | 41 d ago |
| Jul 27, 2026 | PCVX Vaxcyte, Inc. | MOption exercise Common Stock10b5-1 | +16,198 | $2.03 | $33k | 469,445 | Jul 28, 2026 |
| Jul 27, 2026 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stock10b5-1 | -11,783 | $55.52 | $654k | 457,662 | Jul 28, 2026 |
| Jul 27, 2026 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stock10b5-1 | -4,415 | $55.93 | $247k | 453,247 | Jul 28, 2026 |
| Jul 27, 2026 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stockindirect: By Children's Trust10b5-1 | -756 | $55.52 | $42k | 133,459 | Jul 28, 2026 |
| Jul 27, 2026 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stockindirect: By Children's Trust10b5-1 | -244 | $55.96 | $14k | 133,215 | Jul 28, 2026 |
| Jul 27, 2026 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stockindirect: By Children's Trust10b5-1 | -622 | $55.54 | $35k | 133,593 | Jul 28, 2026 |
| Jul 27, 2026 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stockindirect: By Children's Trust10b5-1 | -378 | $55.91 | $21k | 133,215 | Jul 28, 2026 |
| Jul 27, 2026 | PCVX Vaxcyte, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -16,198 | $0.00 | $0 | 137,000 | Jul 28, 2026 |
| Jun 26, 2026 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stock10b5-1 | -6,683 | $54.28 | $363k | 468,020 | Jun 26, 2026 |
| Jun 26, 2026 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stock10b5-1 | -9,137 | $55.27 | $505k | 458,883 | Jun 26, 2026 |
| Jun 26, 2026 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stock10b5-1 | -6,417 | $56.12 | $360k | 452,466 | Jun 26, 2026 |
| Jun 26, 2026 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stockindirect: By Children's Trust10b5-1 | -312 | $54.35 | $17k | 134,903 | Jun 26, 2026 |
| Jun 26, 2026 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stockindirect: By Children's Trust10b5-1 | -356 | $55.23 | $20k | 134,547 | Jun 26, 2026 |
| Jun 26, 2026 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stockindirect: By Children's Trust10b5-1 | -332 | $55.99 | $19k | 134,215 | Jun 26, 2026 |
| Jun 26, 2026 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stockindirect: By Children's Trust10b5-1 | -207 | $54.22 | $11k | 135,008 | Jun 26, 2026 |
| Jun 26, 2026 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stockindirect: By Children's Trust10b5-1 | -602 | $55.30 | $33k | 134,406 | Jun 26, 2026 |
| Jun 26, 2026 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stockindirect: By Children's Trust10b5-1 | -191 | $56.27 | $11k | 134,215 | Jun 26, 2026 |
| Jun 23, 2026 | LONA Athira Pharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +28,000 | $0.00 | $0 | 28,000 | Jun 24, 2026 |
| Jun 18, 2026 | PCVX Vaxcyte, Inc. | MOption exercise Common Stock10b5-1 | +225 | $1.79 | $403 | 497,164 | Jun 18, 2026 |
| Jun 18, 2026 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stock10b5-1 | -225 | $52.51 | $12k | 496,939 | Jun 18, 2026 |
| Jun 18, 2026 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stock10b5-1 | -22,236 | $52.50 | $1.2M | 474,703 | Jun 18, 2026 |
| Jun 18, 2026 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stockindirect: By Children's Trust10b5-1 | -1,000 | $52.50 | $53k | 135,215 | Jun 18, 2026 |
| Jun 18, 2026 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stockindirect: By Children's Trust10b5-1 | -1,000 | $52.50 | $53k | 135,215 | Jun 18, 2026 |
| Jun 18, 2026 | PCVX Vaxcyte, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -225 | $0.00 | $0 | 0 | Jun 18, 2026 |
| Apr 9, 2026 | LONA Athira Pharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +28,000 | $0.00 | $0 | 28,000 | Apr 13, 2026 |
| Mar 9, 2026 | PCVX Vaxcyte, Inc. | FTax withholding Common Stock | -3,685 | $59.32 | $219k | 496,939 | Mar 11, 2026 |
| Feb 26, 2026 | PCVX Vaxcyte, Inc. | AGrant or award Common Stock | +105,110 | $0.00 | $0 | 506,018 | Mar 2, 2026 |
| Feb 28, 2026 | PCVX Vaxcyte, Inc. | FTax withholding Common Stock | -2,863 | $61.98 | $177k | 503,155 | Mar 2, 2026 |
| Mar 2, 2026 | PCVX Vaxcyte, Inc. | FTax withholding Common Stock | -2,531 | $61.98 | $157k | 500,624 | Mar 2, 2026 |
| Feb 26, 2026 | PCVX Vaxcyte, Inc. | AGrant or award Stock Option (right to buy)derivative | +175,698 | $0.00 | $0 | 175,698 | Mar 2, 2026 |
| Jan 14, 2026 | PCVX Vaxcyte, Inc. | GGift Common Stock | -100,000 | $0.00 | $0 | 400,908 | Jan 16, 2026 |
| Sep 8, 2025 | PCVX Vaxcyte, Inc. | FTax withholding Common Stock | -7,356 | $32.41 | $238k | 500,908 | Sep 10, 2025 |
| Sep 2, 2025 | PCVX Vaxcyte, Inc. | FTax withholding Common Stock | -2,857 | $31.56 | $90k | 516,247 | Sep 4, 2025 |
| Sep 2, 2025 | PCVX Vaxcyte, Inc. | FTax withholding Common Stock | -4,563 | $31.56 | $144k | 511,684 | Sep 4, 2025 |
| Sep 2, 2025 | PCVX Vaxcyte, Inc. | FTax withholding Common Stock | -3,420 | $31.56 | $108k | 508,264 | Sep 4, 2025 |
| May 30, 2025 | LONA Athira Pharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +20,900 | $0.00 | $0 | 20,900 | Jun 3, 2025 |
| Apr 4, 2025 | PCVX Vaxcyte, Inc. | MOption exercise Common Stock | +15,781 | $5.35 | $84k | 514,023 | Apr 7, 2025 |
| Apr 4, 2025 | PCVX Vaxcyte, Inc. | MOption exercise Common Stock | +4,752 | $20.93 | $99k | 518,775 | Apr 7, 2025 |
| Apr 4, 2025 | PCVX Vaxcyte, Inc. | MOption exercise Stock Option (right to buy)derivative | -15,781 | $0.00 | $0 | 186,936 | Apr 7, 2025 |
| Apr 4, 2025 | PCVX Vaxcyte, Inc. | MOption exercise Stock Option (right to buy)derivative | -4,752 | $0.00 | $0 | 298,360 | Apr 7, 2025 |
| Dec 9, 2024 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stockindirect: By Children's Trust10b5-1 | -961 | $92.06 | $88k | 136,437 | Dec 10, 2024 |
| Dec 9, 2024 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stockindirect: By Children's Trust10b5-1 | -222 | $93.10 | $21k | 136,215 | Dec 10, 2024 |
| Dec 9, 2024 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stockindirect: By Children's Trust10b5-1 | -1,029 | $92.03 | $95k | 136,369 | Dec 10, 2024 |
| Dec 9, 2024 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stockindirect: By Children's Trust10b5-1 | -154 | $93.60 | $14k | 136,215 | Dec 10, 2024 |
| Dec 2, 2024 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stock10b5-1 | -11,349 | $92.06 | $1.0M | 453,952 | Dec 3, 2024 |
| Dec 2, 2024 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stock10b5-1 | -1,409 | $93.06 | $131k | 452,543 | Dec 3, 2024 |
| Dec 2, 2024 | PCVX Vaxcyte, Inc. | SOpen-market sale Common Stock10b5-1 | -2,242 | $94.06 | $211k | 450,301 | Dec 3, 2024 |
Questions about Grant Pickering
Answered from the filings on this page, as of the latest one.
Is Grant Pickering buying or selling?
In the last 12 months Grant Pickering reported 0 open-market buys worth $0 and 3 open-market sells worth $3.6M on SEC Form 4; the latest was sold $1.0M of PCVX on Jul 27, 2026. Grants, option exercises and tax withholding are not counted.
How did Grant Pickering's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Grant Pickering has 0.
Where does Grant Pickering file Form 4?
Grant Pickering has filed Form 4 at PCVX (Vaxcyte, Inc.) as CHIEF EXECUTIVE OFFICER; LONA (Athira Pharma, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.